ANAPTYSBIO, INCANABEarnings & Financial Report
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for inflammatory diseases, immuno-oncology indications, and rare disease conditions. It primarily serves the U.S. market, advancing its innovative product candidate pipeline to address unmet medical needs via rigorous research and clinical development.
ANAB Q4 FY2025 Key Financial Metrics
Revenue
$108.2M
Gross Profit
N/A
Operating Profit
$66.9M
Net Profit
$49.6M
Gross Margin
N/A
Operating Margin
61.8%
Net Margin
45.8%
YoY Growth
151.1%
EPS
$1.64
ANAPTYSBIO, INC Q4 FY2025 Financial Summary
ANAPTYSBIO, INC reported revenue of $108.2M (up 151.1% YoY) for Q4 FY2025, with a net profit of $49.6M (up 327.8% YoY) (45.8% margin).
Key Financial Metrics
| Total Revenue | $108.2M |
|---|---|
| Net Profit | $49.6M |
| Gross Margin | N/A |
| Operating Margin | 61.8% |
| Report Period | Q4 FY2025 |
ANAPTYSBIO, INC Annual Revenue by Year
ANAPTYSBIO, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $234.6M).
ANAPTYSBIO, INC Quarterly Revenue & Net Profit History
ANAPTYSBIO, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $108.2M | +151.1% | $49.6M | 45.8% |
| Q3 FY2025 | $76.3M | +154.3% | $15.1M | 19.8% |
| Q2 FY2025 | $22.3M | +102.9% | $-38.6M | -173.5% |
| Q1 FY2025 | $27.8M | +286.8% | $-39.3M | -141.6% |
| Q4 FY2024 | $43.1M | +378.8% | $-21.8M | -50.5% |
| Q3 FY2024 | $30.0M | +804.7% | $-32.9M | -109.4% |
| Q2 FY2024 | $11.0M | +217.1% | $-46.7M | -425.3% |
| Q1 FY2024 | $7.2M | +422.5% | $-43.9M | -612.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.2M | $11.0M | $30.0M | $43.1M | $27.8M | $22.3M | $76.3M | $108.2M |
| YoY Growth | 422.5% | 217.1% | 804.7% | 378.8% | 286.8% | 102.9% | 154.3% | 151.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $405.8M | $427.4M | $493.4M | $483.8M | $422.1M | $335.3M | $353.1M | $364.4M |
| Liabilities | $358.1M | $417.5M | $409.1M | $413.0M | $388.0M | $380.0M | $382.5M | $327.2M |
| Equity | $47.8M | $9.9M | $84.4M | $70.9M | $34.0M | $-44.7M | $-29.4M | $37.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37.3M | $-21.3M | $-10.1M | $-66.7M | $-10.7M | $-40.2M | $-27.4M | $98.0M |